Peptides in skincare: dosage in studies

Not a recommendation, not treatment guidance. This page shows only what published human studies used, with sources. This site does not say how much anyone should use of any substance. The content and quality of a product bought online or as a supplement are not controlled like a medicine's.

In human studies of skincare peptides, the dose is the concentration of the peptide in the cream. In the studies in the table, the cream was used for 30 days to 12 weeks [1]A [2]B.

The same acetyl hexapeptide has been used at very different concentrations: 10% in the first study and 0.005% in a blepharospasm trial, which according to the authors matched the concentration used in cosmetics [2]B [3]A.

Doses used in studies

Doses used in published human studies. Not a recommendation.
StudyParticipantsDoseFrequencyDurationSource and level
Robinson 2005 (palmitoyl pentapeptide-4) 93 women aged 35-55, comparing the two sides of the face Moisturiser with 3 ppm palmitoyl pentapeptide-4, on the face Not reported 12 weeks [1]A
Blanes-Mira 2002 (acetyl hexapeptide-8, Argireline) 10 healthy women Emulsion with 10% acetyl hexapeptide, on the skin Not reported 30 days [2, 4]B
Lungu 2013 (acetyl hexapeptide-8) 24 people with blepharospasm, 12 of whom received the peptide Emulsion with 0.005% acetyl hexapeptide-8, on the eyelids Twice a day Until symptoms returned to baseline (3.7 months on average in the peptide group) [3]A

Evidence levels: A = randomised human trial or meta-analysis · B = observational human study or case series · C = animal study · D = cell or laboratory study · E = not peer-reviewed

Notes

The abstracts of Robinson 2005 and Blanes-Mira 2002 do not say how often the cream was applied [1]A [2]B.

The abstract of Blanes-Mira 2002 describes no comparison group; the number of participants comes from a later article [2, 4]B.

What points the other way or is uncertain

A serum containing Argireline (acetyl hexapeptide) did not reduce wrinkles significantly over four weeks in a double-blind split-face comparison in 19 women [4]B.

In the blepharospasm trial the difference from placebo was not statistically significant, and the authors suggested the low concentration may have limited the effect [3]A.

In a meta-analysis of 19 randomised trials, the pooled effect of peptides on wrinkles was small and driven mainly by peptides taken by mouth. Effects on skin elasticity were inconsistent [5]A.

More on this

Read the research yourself: sources

  1. Robinson LR, Fitzgerald NC, Doughty DG, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. PMID 18492182
  2. Blanes-Mira C, Clemente J, Jodas G, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. PMID 18498523
  3. Lungu C, Considine E, Zahir S, et al. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol. 2013;20(3):515-518. PMID 23146065
  4. Henseler H. Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia Complexion Analysis camera system for objective skin analysis. GMS Interdiscip Plast Reconstr Surg DGPW. 2023;12:Doc09. PMID 38024099
  5. Nukaly HY, Halawani IR, Irtaza HM, et al. Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). 2026;13:1618306. PMID 41924746

Sources checked in PubMed on 12 Oct 2026. Concentration, frequency and group sizes for Lungu 2013 are from its full text; the number of participants in Blanes-Mira 2002 (10) is from the full text of Henseler 2023 [4]. Other details were checked from the abstracts, which do not report how often the products were used.

Content is general information about research, not medical advice. If you have symptoms, contact a healthcare professional.